Tags : Superiority

BMS’ Deucravacitinib Demonstrate Superiority Over Otezla (apremilast) in P-III POETYK

Tuba Khan February 3, 2021

Shots: The P-III POETYK PSO-2 study involves assessing deucravacitinib (6mg, qd) vs PBO & Otezla (30mg, bid) in 1,020 patients with moderate to severe plaque psoriasis The trial met its […]readmore

Pharma

Eli Lilly Reports Superiority Results of Taltz (ixekizumab) in P-IV

Vartika Singh August 13, 2019

Shots: The P-IV IXORA-R study involves assessing of Taltz (160 mg at wk 0, followed by 80 mg at wks. 2, 4, 6, 8, 10, and 12, then 80 mg, […]readmore

Tags : Superiority

BMS’ Deucravacitinib Demonstrate Superiority Over Otezla (apremilast) in P-III POETYK

Eli Lilly Reports Superiority Results of Taltz (ixekizumab) in P-IV

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Superiority

BMS’ Deucravacitinib Demonstrate Superiority Over Otezla (apremilast) in P-III POETYK

Eli Lilly Reports Superiority Results of Taltz (ixekizumab) in P-IV

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company